Avandia

Avandia Linked to Heart Attack, Stroke, Cardiovascular Disease

Avandia quickly became a blockbuster drug after its introduction in the U.S. in 1999. Eight years later, a landmark analysis indicated the drug was linked to a substantially higher risk of heart attack or cardiovascular-related death than other similar drugs.

The FDA placed a black box warning on Avandia in 2007. Even though the FDA considered removing the drug from the market at that time, Avandia’s manufacturer insisted that certain studies showed no increased health risks from taking Avandia. In July 2010, an FDA panel voted not to remove Avandia from the market, but called for stronger restrictions when writing prescriptions.

Though Avandia has been criticized for safety issues since 2007, the drug’s manufacturer, GlaxcoSmithKline, continued to hide the truth about the medication’s harmful side effects and even lobbied the FDA to keep the drug on the market. The manufacturer went so far as mounting a multi-million dollar ad campaign to promote Avandia after the black box warning was placed on the drug, and Avandia sales soared. As a result of this ad campaign, several states are suing GlaxcoSmithKline for fraudulent advertising. Baron & Budd represents a number of states in lawsuits against the drugs’s manufacturer, GlaxcoSmithKline, for fraudulent marketing of Avandia.

Baron & Budd helped negotiate a settlement with Avandia manufacturer GlaxoSmithKline in 2012 for more than 20,000 claims alleging that Avandia can cause hearts attacks. Thousands of Avandia claims are still pending in litigation.